Clarium vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $27M Series A led by Northzone with Kaiser Permanente Ventures and General Catalyst. First AI supply chain resiliency platform built specifically for hospital systems.
About
Clarium is the first AI-powered supply chain resiliency platform built specifically for hospital health systems, providing real-time intelligence about supply chain disruptions before they cause care delivery failures. The company raised $27 million in Series A financing led by Northzone, with Kaiser Permanente Ventures, General Catalyst, and Cleveland Clinic participating. A former Kaiser Permanente Chief Supply Chain Officer joined as strategic advisor in Q1 2026.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.